What changed for Non-Alcoholic Fatty Liver Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Non-Alcoholic Fatty Liver Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 217 to 218 (+1)
- Trials on record 1,579 to 1,592 (+13)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Non-Alcoholic Fatty Liver Disease yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 87 trials tracked for Non-Alcoholic Fatty Liver Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04365868 · results posted 30 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04365868) enrolled 357 adults across three groups: 118 received a placebo (a dummy treatment with no active ingredient), 119 received a lower dose of a drug called belapectin (2 mg/kg of lean body mass), and 120 received a higher dose of belapectin (4 mg/kg of lean body mass). The trial ran for approximately 18 months and was primarily measuring how many people in each group developed new varicose veins in the food pipe (known as oesophageal varices), which are a complication of liver scarring. Most participants completed...
-
NCT05338034 · results posted 28 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 87 people in total, split across four groups: 22 received a placebo (a dummy treatment with no active ingredient), 22 received a 3 mg dose of HPG1860, 21 received a 5 mg dose, and 22 received an 8 mg dose. The trial was measuring the safety and tolerability of the drug (meaning how many people experienced unwanted side effects or reactions), as well as changes in the amount of fat in participants' livers over 12 weeks, measured using a specialised type of MRI scan. The reported data shows that the primary thing being...
-
NCT06007651 · results posted 13 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06007651) tested a drug called LY3885125 and was split into two parts. Part A looked at single doses (SAD = single ascending dose), where participants received one of five increasing dose levels of the drug or a placebo (a dummy treatment with no active ingredient). Part B was designed to look at multiple doses over time (MAD = multiple ascending dose), but the reported data shows that zero participants were enrolled or dosed in Part B. In total, 49 people started Part A across all groups, with 47 completing it; 2 particip...
-
NCT04929483 · results posted 6 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04929483) tested a medicine called pegozafermin in people with a liver condition called NASH (non-alcoholic steatohepatitis), which involves fat build-up and inflammation in the liver. The main 24-week study enrolled 222 people across three pegozafermin dose groups (15 mg weekly, 30 mg weekly, and 44 mg every two weeks) and a placebo group of 71 people. A further extension study followed most of these participants for another 24 weeks. The trial was primarily measuring two things in liver tissue samples: whether the NASH s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04971785 · results posted 26 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04971785) enrolled 457 adults with a liver condition called NASH (nonalcoholic steatohepatitis), which involves liver inflammation and scarring. Participants were divided into four groups and received different combinations of two medicines — semaglutide and cilofexor/firsocostat — or matching dummy treatments (placebos). The trial ran for 72 weeks and was mainly measuring whether participants' liver scarring (fibrosis) improved by at least one stage without their liver inflammation getting worse. The reported data shows...
-
NCT04202354 · results posted 3 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04202354) enrolled 50 people in total across eight groups. Most groups received different doses of an investigational drug called ARO-HSD — either 25 mg, 50 mg, 100 mg, or 200 mg — while 16 participants received a placebo (an inactive dummy injection used for comparison). The trial was primarily looking at how many participants experienced unwanted medical events (called adverse events) that were thought to be possibly or probably linked to the study drug. It also measured how the drug moved through the body — for example,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04004403 · results posted 25 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 80 adults across four groups of 20 people each: one group followed an alternate day fasting plan (eating very little every other day), one group did supervised exercise, one group combined both approaches, and one group acted as a control (no intervention). The trial was measuring changes in liver fat (the primary focus), body weight, and several blood markers related to liver health and blood sugar. Of the 80 who started, 74 completed the trial — all 20 in both the combination and control groups finished, 19 of 20 in...
-
NCT05364931 · results posted 3 September 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called cotadutide and involved 54 people in total. Participants were split into four groups: 17 received a lower dose of cotadutide (300 micrograms), 18 received a higher dose (600 micrograms), 9 received a matching dummy treatment (placebo) for the higher dose, and 10 received a matching dummy treatment for the lower dose. Not everyone finished the trial — 14 people completed the lower-dose cotadutide group, 14 completed the higher-dose group, 5 completed one placebo group, and 8 completed the other. The tria...
-
NCT07052682 · results posted 19 August 2025
According to the results reported on ClinicalTrials.gov, this trial involved 11 participants, all of whom received a treatment called ontamalimab. Seven participants completed the study, while four did not finish. The trial was primarily measuring whether participants experienced any unexpected medical events (called treatment-emergent adverse events, or TEAEs) after receiving the treatment, as well as whether there were any notable changes in blood test results, heart tracings (ECGs), vital signs such as blood pressure and pulse, and body weight. The reported data shows that out of the 11 pa...
-
NCT05211284 · results posted 16 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05211284) was designed to compare a medication called saroglitazar magnesium (4 mg) against a placebo (a dummy treatment with no active ingredient) in people with liver disease. The trial aimed to measure changes in the amount of fat stored in the liver, liver stiffness, and certain markers in the blood related to liver scarring and fat. In total, only four people were enrolled — three in the saroglitazar magnesium group and one in the placebo group. The reported data shows that none of the four participants completed the...
-
NCT02500147 · results posted 2 July 2025
According to the results reported on ClinicalTrials.gov, this trial set out to compare the amount of fat in the liver between two small groups of adolescents and young women with Polycystic Ovary Syndrome (PCOS) — one group taking metformin (a medicine commonly used for blood sugar) and one group taking a placebo (a dummy treatment with no active ingredient). The trial enrolled 3 participants in total — 1 in the metformin group and 2 in the placebo group — and none of them completed the study. Because so few people were enrolled and no one finished, the results should be interpreted with great...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02443116 · results posted 26 June 2025
According to the results reported on ClinicalTrials.gov, this trial tested a drug called aldafermin across three separate parts, each looking at different doses. In total, the trial enrolled 254 participants across all three parts — 82 in Part 1, 94 in Part 2, and 78 in Part 3. The main thing being measured in all three parts was the change in the amount of fat stored in the liver, which was assessed using a type of MRI scan. Parts 1 and 3 also included groups who received a placebo (a dummy treatment with no active ingredient), allowing the researchers to compare results. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04210245 · results posted 26 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04210245) enrolled 160 participants across four groups: 7 people received a daily 0.3 mg dose, 42 received a daily 1 mg dose, 55 received a daily 3 mg dose, and 56 received a placebo (a dummy treatment with no active ingredient). The trial's main focus was measuring changes in something called the Enhanced Liver Fibrosis (ELF) score — a blood test used to estimate the level of liver scarring (fibrosis). A higher ELF score indicates more severe disease. This score was measured at the start of the trial and again at 48 weeks...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04321031 · results posted 21 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04321031) enrolled 255 adults across seven groups to study a liver condition called NASH (non-alcoholic steatohepatitis), which involves inflammation and cell damage in the liver. Participants were assigned to receive either a placebo (inactive treatment), one of four doses of an investigational medicine called PF-06865571 (taken twice daily), or one of those doses combined with a second investigational medicine called PF-05221304. The trial ran for 48 weeks and was primarily measuring how many participants showed signs of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04052516 · results posted 28 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04052516) enrolled 280 people across three groups: 92 received a placebo (a dummy treatment with no active ingredient), 93 received a lower dose of icosabutate (300 mg), and 95 received a higher dose (600 mg). The trial was measuring changes in liver tissue in people with a condition called NASH (non-alcoholic steatohepatitis), a form of liver disease involving inflammation and cell damage. The main thing the trial looked at was whether signs of NASH visible on a liver biopsy had resolved — specifically, whether certain ty...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05792423 · results posted 14 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 healthy adult volunteers to test a new ultrasound method called "Conditionally Increased Output" (CIO) enhanced ultrasound, which is designed to measure how stiff the liver is. Stiffer livers can be a sign of liver disease. Twenty-two of the 24 participants completed the study, and two did not finish. The trial was primarily focused on monitoring whether the ultrasound procedure had any impact on the liver, by checking blood markers of liver health before and after the scan. The reported data shows that three spec...
-
NCT04166773 · results posted 24 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04166773) enrolled 190 adults in total, split across four groups: 47 people received 5 mg of tirzepatide, 47 received 10 mg, 48 received 15 mg, and 48 received a placebo (a dummy treatment with no active ingredient). The trial ran for 52 weeks and was primarily measuring whether tirzepatide could clear up a liver condition called NASH (a form of liver inflammation linked to fat build-up) without causing the liver scarring — known as fibrosis — to get worse. A number of secondary measures were also tracked, including change...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03938246 · results posted 19 December 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called TVB-2640 in people with excess fat in their liver. A total of 142 people started the trial across two countries — the United States and China. Participants were split into six groups: some received TVB-2640 at different doses (25 mg, 50 mg, or 75 mg), and others received a placebo (a dummy treatment with no active ingredient). The main thing being measured was how much the amount of fat in the liver changed after 12 weeks, using a specialised type of MRI scan. The reported data shows that, on average,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04771273 · results posted 3 December 2024
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of a medicine called survodutide (2.4 mg, 4.8 mg, and 6.0 mg) against a placebo (an inactive dummy treatment) in people with a liver condition called NASH — a form of liver disease where fat builds up and causes inflammation and damage. A total of 295 people were enrolled across the four groups and went through an initial dose-build-up period followed by a maintenance period lasting 48 weeks in total. The trial's main goal was to measure whether liver tissue, examined under a microscope via a biops...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03061721 · results posted 24 October 2024
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of a medicine called saroglitazar magnesium (1 mg, 2 mg, and 4 mg) against a dummy pill (placebo) in people with a liver condition. A total of 106 people were enrolled across the four groups — 26 in the 1 mg group, 25 in the 2 mg group, 27 in the 4 mg group, and 28 in the placebo group. Not everyone finished the trial: 5 people in the 2 mg group and 3 in the placebo group did not complete it. The main thing the trial was measuring was the change in a liver enzyme called ALT (alanine aminotransferas...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03783195 · results posted 23 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people in total — 8 in a group with a high genetic risk score (a measure based on genes linked to fat processing in the liver) and 7 in a group with a low genetic risk score. All 15 participants completed the study. The trial was measuring whether people's genetic profile made a difference to how their liver fat and certain blood fats changed over a 3-week period. Liver fat was measured in two ways — using a specialised ultrasound scan called elastography (FibroScan) and an MRI scan — and blood levels of specific f...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03863574 · results posted 15 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03863574) enrolled 16 people in total across three groups: 6 received saroglitazar magnesium at a 2 mg dose, 7 received it at a 4 mg dose, and 3 received a placebo (a dummy treatment with no active ingredient). All 16 participants completed the study. The trial was measuring changes in liver disease activity over 24 weeks in people with a condition called NASH (non-alcoholic steatohepatitis, a form of fatty liver disease). The main thing being tracked was a liver scoring system called the NAFLD Activity Score, or NAS — a n...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04283942 · results posted 23 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04283942) enrolled 60 people in total — 30 in an intermittent calorie restriction (ICR) group, where calories were reduced on certain days in a pattern, and 30 in a continuous calorie restriction (CCR) group, where calories were reduced steadily every day. Both groups had 28 people complete the study, with 2 in each group not finishing. The trial was primarily measuring changes in the amount of fat stored in the liver, and also tracked body weight, blood sugar levels, a longer-term blood sugar marker called HbA1c (a measur...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04857437 · results posted 20 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04857437) tested a investigational medicine called PF-07202954 in a small group of healthy adult volunteers. The study was conducted in two parts, though only Part 1 appears to have reported results. In Part 1, participants were assigned to one of eight sub-groups across two cohorts, receiving different single doses of the medicine (10 mg, 30 mg, 100 mg, 300 mg, or 600 mg) or a placebo (a dummy treatment with no active ingredient), and some doses were given with different meals or in a fasted state. The total number of par...
-
NCT02548351 · results posted 5 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02548351) enrolled 2,477 adults in total — 825 received a 10 mg dose of obeticholic acid (OCA), 827 received a 25 mg dose of OCA, and 825 received a placebo (a dummy treatment with no active ingredient). All participants had a liver condition called NASH (a form of fatty liver disease that can cause scarring). The trial was measuring whether OCA delayed or reduced serious liver-related events over time, as well as whether it changed the level of liver scarring (called fibrosis) seen in tissue samples taken by biopsy. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04267393 · results posted 4 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04267393) enrolled 124 adults in total — 40 in the placebo group, 42 in Treatment 1, and 42 in Treatment 2. The trial was looking at people with a liver condition called NASH (non-alcoholic steatohepatitis), which involves scarring (fibrosis) of the liver. The main thing researchers were measuring was whether liver scarring improved by at least one stage on a standard scoring scale, assessed through a liver biopsy taken after 12 weeks of treatment. The reported data shows that for the primary measure — the percentage of p...
-
NCT03987451 · results posted 29 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 71 adults in total — 47 received semaglutide 2.4 mg (a weekly injection) and 24 received a placebo (an inactive treatment). Of those, 45 and 23 participants respectively completed the study. The trial was looking at a liver condition called non-alcoholic steatohepatitis (NASH), which involves inflammation and damage to liver cells, often alongside scarring (fibrosis). The main thing the trial measured after 48 weeks was how many participants showed at least one stage of improvement in liver scarring without their NASH...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04031729 · results posted 24 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 80 adults in total — 40 in a group that received aspirin and 40 in a group that received a placebo (a dummy pill with no active ingredient). Of those, 37 in the aspirin group and 34 in the placebo group completed the study. The trial was measuring changes in the amount of fat stored inside the liver, using a specialised scanning technique called 1H-MRS (a type of MRI-based measurement that can estimate liver fat levels). The reported data shows that, on average, the aspirin group's liver fat level changed by −6.6 per...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04583423 · results posted 29 April 2024
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of a drug called MK-3655 (50 mg, 100 mg, and 300 mg) against a placebo (an inactive treatment) in people with a liver condition called non-alcoholic steatohepatitis, or NASH — a form of liver disease involving fat build-up, inflammation, and cell damage. A total of 183 people started the trial across the four groups. The trial ran for 52 weeks and was primarily measuring how many participants showed signs of NASH resolution on liver biopsy without their liver scarring (fibrosis) getting worse, as w...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04048135 · results posted 2 April 2024
According to the results reported on ClinicalTrials.gov, this trial tested a drug called pegozafermin in people with a liver condition. The trial had two parts. Part 1 enrolled 81 people across six different dose groups (ranging from 3 mg to 36 mg, given either once a week or once every two weeks) plus a placebo group of 19 people who received a dummy treatment. Part 2 enrolled a further 20 people, all receiving 27 mg of pegozafermin once a week. The trial was measuring how the drug moved through the body (for example, how quickly it reached peak levels in the blood and how long it took to cle...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 87 reported results for Non-Alcoholic Fatty Liver Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research money has been directed toward Non-Alcoholic Fatty Liver Disease, which tells patients that this condition has been taken seriously as a significant health priority. However, the direction of that funding has been falling year on year, which may signal a shift in research priorities or a maturing of the foundational science. Pat...
See the full Non-Alcoholic Fatty Liver Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.